基于肠道微生物群探讨类风湿关节炎发病机制及甲氨蝶呤疗效
Exploration of pathogenesis of rheumatoid arthritis and efficacy of methotrexate based on intestinal microbiota
张瑞 1张莉 2毛婧 1李文花 1张宪萌 1沈海丽2
作者信息
- 1. 兰州大学第二临床医学院(兰州 730000)
- 2. 兰州大学第二医院风湿免疫科(兰州 730030)
- 折叠
摘要
类风湿关节炎(rheumatoid arthritis,RA)是最常见的免疫介导性疾病之一,肠道微生物群与患者免疫系统之间的相互作用可能在RA的发生发展中起到一定作用.甲氨蝶呤(methotrexate,MTX)作为治疗RA的一线药物,肠道微生物及其酶产物可以通过直接和间接机制影响药物的生物利用度、临床疗效和毒性.因此了解肠道微生物群影响RA的机制、肠道微生物群对MTX疗效的影响至关重要.该文就肠道微生物群可能致RA发病的机制,以及肠道微生物群在MTX药物代谢和治疗反应中的作用机制及影响作一综述.
Abstract
Rheumatoid arthritis(RA)is one of the most common immune-mediated diseases,and the interaction between the intestinal microbiota and the patient's immune system may play a role in the occurrence and development of RA.Methotrexate(MTX),as a first-line drug for the treatment of RA,can be directly and indirectly influenced by intestinal microbiota and its enzyme products to affect the bioavailability,clinical efficacy,and toxicity of the drug.Therefore,it is crucial to understand the mechanism by which intestinal microbiota affects RA and the impact of intestinal microbiota on the efficacy of MTX.This article provides a review of the mechanisms by which intestinal microbiota may contribute to the pathogenesis of RA,as well as the role and impact of intestinal microbiota in MTX drug metabolism and treatment response.
关键词
肠道微生物群/甲氨蝶呤/类风湿关节炎/免疫应答Key words
Intestinal microbiota/methotrexate/rheumatoid arthritis/immune response引用本文复制引用
基金项目
甘肃省科技计划(22JR5RA955)
甘肃省教育科技创新项目(2022B-057)
出版年
2024
NETL
NSTL
万方数据